Infographic: Vaccinating Against Tumors

Cancer vaccines offer the opportunity to use the patient’s own immune system in the fight against tumors.

Written byShelby Bradford, PhD
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
TK
modified from © ISTOCK.COM, ttsz, Rungnaree Jaitham, Shonyjade, PsychoBeard; designed by ashleigh campsall

1. Antigen preparation: Scientists can produce cancer vaccines against tumors by using the patient’s tumor as a source of antigen or by synthesizing peptides from tumor antigens.

2. Antigen delivery: Researchers use different vaccine platforms to deliver the antigens: patient-derived dendritic cells, adeno-associated viral vectors, and lipid nanoparticles.

3. Antigen presentation: Once administered, these antigens eventually find their way to patient dendritic cells, or are immediately expressed on dendritic cells if they are used as the vehicle. The dendritic cells travel to lymph nodes to activate antigen-specific T cells.

4. Anti-tumor immunity: Once activated, these tumor-antigen-specific T cells will multiply (a) and travel to the tumor, where they help target the tumor cells for destruction (b). Some activated T cells will become memory cells (c, shown in purple); these will reside in the lymph node or nearby tissue to protect the body against future recurrences of the same type of cancer.

Read the full story.

Related Topics

Meet the Author

  • Shelby Bradford, PhD

    Shelby is an Assistant Editor at The Scientist. She earned her PhD in immunology and microbial pathogenesis from West Virginia University, where she studied neonatal responses to vaccination. She completed an AAAS Mass Media Fellowship at StateImpact Pennsylvania, and her writing has also appeared in Massive Science. Shelby participated in the 2023 flagship ComSciCon and volunteered with science outreach programs and Carnegie Science Center during graduate school. 

    View Full Profile

Published In

Spring 2024 cover
Spring 2024

Turning on the Bat Signal

Research into bat immune systems may help keep humans safe from viral attacks.

Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies